关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
+ F* `* l$ ?0 v8 K    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
3 k! h8 v9 ?7 K0 E3 B3 }3 w( u
作者：来自澳大利亚
; w' _0 C6 r7 q9 {) y来源：Haematologica. 2011.8.9.
Dear Group,

3 v4 k) {) z* ^% e; USome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
* w- Q  S. D6 p# W  W8 b! Ltherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
" k1 y% K. l5 I/ q# udoes spike up the immune system so I hope more reports come out on this issue.
) {4 _3 Q9 l3 G
! a9 e/ R& M1 X) u4 [9 d( LThe remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
1 c$ b4 R' `% sdifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.
2 b3 [" z) W2 E- e+ M/ o
2 h% k* }  s; F; hBest Wishes,
Anjana
( ]$ T1 g3 t+ r: e3 ?, q


/ g1 F" b. R1 v4 nHaematologica. 2011 Aug 9. [Epub ahead of print]
: P2 W1 e6 o- {8 R1 ?4 }+ ]Durable complete molecular remission of chronic myeloid leukemia following
/ ]2 D# y2 s9 V3 Idasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
. g+ i* I) D! l- R4 {$ e$ aAdelaide, Australia;
# X# t5 y' c% u8 P
Abstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
. C  A& N8 @" s4 Z" a( cdurable complete molecular response might remain in CMR after stopping
2 ~& i+ L  k6 S& q* B0 Atreatment. Previous reports of patients stopping treatment in complete molecular
* N+ ?/ ?! [' P8 r( [; }" X- F$ k7 z! Fresponse have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
$ i+ Y9 q. ?, E7 Itreatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
) U# n3 }0 g1 B" q  P* H; Lshow that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
( Q) b4 i$ ]5 qwho relapsed and in one patient in remission. Our results suggest that the
7 u  f. X2 |1 h8 @+ @3 ^- v" Tcharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
disease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
- y: l- J& i2 C/ h# W    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

3 V' |. Z. i* L, K! }/ \9 l作者：来自法国STIM试验
/ Z, p' E) G, x/ i  G& s6 \来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事